Table 1.

Summary of subject demographics

Demographics	Ketoconazole trial 30 mg TLV (n = 19)	Placebo (n = 5)	Rifampicin trial (n = 15)
Age (years) [Mean (range)]	31 (19–45)	27 (20–39)	26 (18–42)
Weight (kg) [Mean (range)]	75.0 (59.0–89.4)	66.1 (54.2–77.5)	72.0 (52.0−91.0)
Gender, n (%)
Male	12 (63.1)	2 (40.0)	9 (60.0)
Female	7 (36.8)	3 (60.0)	6 (40.0)
Race (n)
Caucasian	14 (73.7)	3 (60.0)	10 (66.7)
Other	5 (26.3)	2 (40.0)	5 (33.3)

TLV, tolvaptan.